SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):321P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Coulot, J.
Right arrow Articles by Baudin, E.
PubMed
Right arrow Articles by Coulot, J.
Right arrow Articles by Baudin, E.

Oncology-Basic Science: Therapy, Metrics & Intervention

Therapy, Metrics & Intervention Posters

Impact of 177Lu-octreotate therapy on the spleen

Jeremy Coulot1, Sophie Leboulleux2, Jean Lumbroso2, Clarisse Dromain3, Michel Ducreux4, Joel Guigay4, Martin Schlumberger2, Dik Kwekkeboom5 and Eric Baudin2

1 Physics - Imaging Research; 2 Nuclear Medicine and Endocrine Tumors; 3 Radiology; 4 Medicine, Institut Gustave-Roussy, Villejuif, France; 5 Nuclear Medicine, Erasmus Medical Center, University Hospital Rotterdam, Rotterdam, Netherlands

1363

Objectives: The aim of this retrospective study was to evaluate the impact of 177Lu-octreotate therapy on the spleen, a cible organ of peptide receptor radionuclide therapy (PRRT) in patients treated for metastatic well differentiated gastro-entero-pancreatic endocrine cancers (WD GEP EC).

Methods: Spleen volume was measured on diagnostic CT (5 mm thick slice) performed before (mean delay 10.7 month; range:0.3–47.9) and after (mean delay following last administration of PRRT: 5.7 month; range:1.9–10) treatment with 177Lu-octreotate. Spleen’s contours were semi-automatically delineated and spleen volume was calculated using an image processing workstation (Isogray, Dosisoft, France) in 7 patients (1 female, 6 male, mean age 57 years) referred to the Rotterdam group for PRRT. Five patients received a cumulated activity (CA) of 30 GBq in 4 administrations and 2 patients a mean CA of 21 GBq in 3 administrations.

Results: Mean spleen volume was 222 cm3 (range:127-312) and 180 cm3 (range:89-237) before and after PPRT respectively. A reduction of the spleen volume was observed in all patients after PRRT with a mean reduction of 19 % (range 10-36%). No infectious event occurred after PPRT after a median follow-up of 17 months (range: 7.8-27.1).

Conclusions: These preliminary data shows that 177Lu-octreotate therapy is probably responsible of a reduction in spleen volume. Whether there is a clinical impact will have to be determined on further studies.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Coulot, J.
Right arrow Articles by Baudin, E.
PubMed
Right arrow Articles by Coulot, J.
Right arrow Articles by Baudin, E.